Membrane Protein Solution for Vaccine DevelopmentOnline Inquiry
The whole world is currently facing a significant public health threat due to emerging and reemerging infectious diseases. The emergence, evolution, and spread of pathogens are further accelerated by the increase in global population, increased global travel, and climate change. To date, to prevent and eliminate viral infections and their ensuing ravages, vaccination might be the most effective among public health interventions. Since the development of vaccination in the 18th century, they have become the basis of global public health programs and major socioeconomic benefits.
Viral membrane antigens for vaccine development
Viral pathogens pose a serious threat to public health, as evidenced by the current 2019 coronavirus disease (COVID-19) pandemic, recurrent influenza epidemics, and human immunodeficiency virus (HIV) epidemics. As one of the most effective ways to stop the transmission of infectious diseases, vaccination is widely developed in a variety of ways. Among them, the use of viral proteins as antigens to stimulate the immune system is commonly used to develop protection against infection. Membrane proteins are proteins (conformational antigens) that are expressed on the surface of enveloped viruses, which can be readily recognized by B cells of the immune system, thereby inducing neutralizing antibody production. Viral membrane proteins typically contain extracellular and cytoplasmic regions linked together by a transmembrane structural domain (TM). TM anchors viral proteins to the host cell membrane prior to viral release. These proteins are often the preferred antigens in vaccine development. There is a wide range of viral membrane proteins, such as the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the envelope protein of HIV, and the hemagglutinin (HA) and Matrix 2 (M2) ion channel proteins of influenza virus.
Creative Proteomics provides high-quality and functional membrane protein for vaccine development
Viral membrane proteins are the antigens of choice in vaccine development, and effective vaccines require the synthesis and delivery of these native conformational antigens in lipid membranes to preserve specific epitope structures. With the rapid development of vaccines, Creative Proteomics is your professional and reliable partner. We can help you make great progress in the development of membrane protein-based vaccines. We will be responsible for all aspects of our client's projects, ranging from membrane protein production, biophysical characterization, and hit identification, to candidate drug selection. As one of the leading service providers in the field of membrane protein, we continuously challenge ourselves and strive to offer our customers the finest service. Your project will be executed with the utmost care. Your sensitive information will be strictly protected during the experimentation and transmission process.
Our pure, stable, and functional native membrane proteins can greatly help customers improve their vaccine discovery and development, especially for splitting vaccines and multi-subunit (recombinant) vaccines. In addition, our services can facilitate the discovery and production of new antigens for use in the development of new or improved vaccines. Specifically, our services include the following lists, but are not limited to:
- Membrane protein identification
- Membrane and membrane protein extraction
- Membrane protein production service
- Membrane protein-molecule interaction analysis
- Membrane protein structure determination
- Membrane proteomics service
Creative Proteomics is proud to offer high-quality and functional membrane protein, including viral protein, ion channels, GPCRs, and other membrane targets. We are committed to helping pharmaceutical industries, biotechnology companies and academic teams with membrane protein-based drug discovery, with a focus on small molecule drug discovery, conformational antibody development, and new vaccine formulation.
- Choi, Sengjin, et al. "Displaying and delivering viral membrane antigens via WW domain–activated extracellular vesicles." Science Advances 9.4 (2023): eade2708.
* For Research Use Only. Not for use in diagnostic procedures.